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BACKGROUND:Carbonic anhydrase IX (CAIX) is an enzyme upregulated by hypoxia during tumour development and progression. This
study was conducted to assess if the expression of CAIX in tumour tissue and/or plasma can be a prognostic factor in patients with
non-small cell lung cancer (NSCLC).
METHODS: Tissue microarrays containing 555 NSCLC tissue samples were generated for quantification of CAIX expression. The
plasma level of CAIX was determined by ELISA in 209 of these NSCLC patients and in 58 healthy individuals. The CAIX tissue
immunostaining and plasma levels were correlated with clinicopathological factors and patient outcome.
RESULTS: CAIX tissue overexpression correlated with shorter overall survival (OS) (P¼0.05) and disease-specific survival (DSS)
of patients (P¼0.002). The CAIX plasma level was significantly higher in patients with NSCLC than in healthy individuals (Po0.001).
A high level of CAIX in the plasma of patients was associated with shorter OS (Po0.001) and DSS (Po0.001), mostly in early stage
IþII NSCLC. Multivariate Cox analyses revealed that high CAIX tissue expression (P¼0.002) was a factor of poor prognosis
in patients with resectable NSCLC. In addition, a high CAIX plasma level was an independent variable predicting poor OS (Po0.001)
in patients with NSCLC.
CONCLUSION: High expression of CAIX in tumour tissue is a predictor of worse survival, and a high CAIX plasma level is an
independent prognostic biomarker in patients with NSCLC, in particular in early-stage IþII carcinomas.
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Non-small cell lung cancer (NSCLC) comprises approximately 80%
of lung cancers, and nearly 50% of patients with stage I NSCLC die
within 10 years of diagnosis (Travis et al, 2004; Ou et al, 2007).
Despite major advances in surgical techniques and new strategies
of neoadjuvant treatment, long-term survival is achieved in only
5–10% of NSCLC patients (Stinchcombe and Socinski, 2009). In
this regard, early biomarkers are urgently needed to allow better
clinical management of patients with NSCLC.
Hypoxia is common in various types of solid cancers and is
associated with a more aggressive phenotype (Brahimi-Horn et al,
2007). Stabilisation of the a-subunit of the hypoxia-inducible
transcription factor 1 (HIF-1a) is a critical step in the adaptation
of tumour cells to hypoxia (Pouyssegur et al, 2006). One of the
consequences of HIF-1 activation is upregulation of glycolysis
and hence the production of lactic acid (Pastorekova et al, 2004).
The enzyme carbonic anhydrase IX (CAIX), which is expressed on
the tumour cell surface, catalyses the hydration of cell-generated
carbon dioxide into protons and bicarbonate ions (Pastorekova
et al, 2004). This reaction contributes to an acidic extracellular
microenvironment and intracellular alkalosis, allowing tumour
cells to survive under hypoxic conditions, favouring tumour
growth, invasion, and development (Chiche et al, 2009).
Subsequent studies have shown that CAIX is expressed in only a
few normal tissues (mainly the gastrointestinal tract), whereas it is
ectopically induced under hypoxic conditions and highly over-
expressed in many different cancer cell lines and tumour tissues,
where ca9 is one of the most upregulated gene in a (HIF-1)-
dependent manner (Wykoff et al, 2000). The expression of CAIX is
strongly upregulated by hypoxia and is downregulated by the
wild-type von Hippel-Lindau (pVHL) tumour suppressor protein
(Ohh et al, 2000). CAIX has already been shown to serve as a
surrogate marker of hypoxia and as a prognostic indicator for
many cancers (Loncaster et al, 2001). In some cancer cells, the
VHL gene is mutated leading to strong upregulation of CAIX
(up to 150-fold) as a consequence of constitutive HIF-1 activation
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s(Pouyssegur et al, 2006). A relationship between CAIX tumour
tissue expression, as detected by immunohistochemistry (IHC)
and patient outcome has been reported in a wide variety of
tumours (Bui et al, 2003; Hedley et al, 2003; Trastour et al, 2007;
Choi et al, 2008; Klatte et al, 2009; Korkeila et al, 2009). Previous
studies have reported the prognostic relevance of CAIX over-
expression in NSCLC indicating a potential oncogenic function of
CAIX (Swinson et al, 2003; Kim et al, 2004; Kon-no et al, 2006).
However, these studies performed only a limiting number of IHC
analyses on surgical tumour samples.
Methods that use biological materials obtained by non-
invasive procedures, like plasma, can be helpful in identifying
possible biomarkers for early diagnosis and in the follow-up of
patients with an increased cancer risk. CAIX is a multidomain
protein consisting in an N-terminal proteoglycan-like (PG)
domain, an extracellular catalytic domain (CA), a transmembrane
segment (TM) and a C-terminal intracytoplasmic (IC) tail (Hilvo
et al, 2008). Recent reports have provided evidence that
the extracellular domain of CAIX can be released into body
fluids of patients with kidney or bladder cancers and a high
CAIX plasma level was associated with poor prognosis in these
patients (Zavada et al, 2003; Hyrsl et al, 2009). However, the
CAIX plasma level has not yet been evaluated in patients with
NSCLC.
The aim of this study was to investigate the expression of CAIX
in both tissue and plasma samples from a large cohort of NSCLC
patients to explore the potential role of CAIX as a prognostic
biomarker for NSCLC.
PATIENTS AND METHODS
Patients
Five hundred fifty-five patients who underwent surgery for
NSCLC between January 2001 and January 2008 at the Pasteur
Hospital (Department of Thoracic Surgery, University of Nice,
France) were included in this study. The patients received the
necessary information concerning the study and consent was
obtained from each of them. The study was done with the approval
of the ethics committee (CHU of Nice). The main clinical and
histopathological data are summarised in Table 1. Morphological
classification of the tumours was assigned according to the WHO
criteria (Travis et al, 2004). The tumours were staged according
to the international tumour-node-metastasis system (Mountain,
1997). The median follow-up at the time of analysis was 35 months
(3–102 months) according to the method of Schemper and
Smith, (1996). Among these patients, 122 of 555 (22%) died of
lung cancer.
For the ELISA assay, 209 preoperative plasma samples were
obtained from these patients. The main clinical and histopatho-
logical data are summarised in Table 2. The median follow-up was
15 months (1–66 months). Among these patients 14 of 209 (8%)
died of lung cancer. Plasma samples from 58 healthy individuals
were used as a control for the ELISA assay.
Tissue microarrays (TMAs) and immunohistochemistry
TMAs were constructed from archival paraffin-embedded,
formalin-fixed tissue blocks. Representative tumour regions and
adjacent normal lung tissue were selected for building TMAs
and arrays were designed as previously described (Hofman et al,
2008). Immunohistochemistry for CAIX, HIF-1a and Ki-67 was
performed on serial 4-mm deparaffinised TMA sections by using an
automated single-staining procedure (Benchmark XT, Ventana
Medical Systems, Roche Group Inc., Tucson, AR, USA). Briefly, a
rabbit polyclonal anti-CAIX antibody (clone ab15086, diluted
1:2000, Abcam, Cambridge, MA, USA) was added to each slide
after blocking of endogenous peroxidase and proteins, and the
sections were incubated with a biotinylated mouse anti-rabbit IgG
(Abcam) as the secondary antibody. EDTA-pretreated sections
were immunostained for HIF-1a (mouse, clone 54; diluted 1:10;
BD Biosciences, Heidelberg, Germany) and Ki-67 (rabbit, clone
30–9; diluted 1:100; Ventana Medical Systems). Paraffin-em-
bedded sections from healthy lung tissue exposed under normoxic/
hypoxic conditions were stained for BNIP3 (rabbit, clone ANa40;
diluted 1:250; Sigma-Aldrich, St Louis, MI, USA) and BNIP3L
(rabbit, polyclonal; diluted 1:250, Sigma-Aldrich). 3–30-diamino-
benzidine (Sigma-Aldrich) was the chromogen used in all
reactions. Positive controls for CAIX were biopsy cores of head
and neck squamous cell carcinoma, which has previously been
established as positive for CAIX (Koukourakis et al, 2001).
Automated image analysis
After antibody staining, images were acquired using automated
quantitative analysis (Hofman et al, 2008). The CAIX signal was
measured on a grayscale of 0 (black) to 255 (white) and expressed
as target signal intensity relative to plasma membrane compart-
ment area. Grey values ranged between 0 and 152, and a value
superior or equal to 50 was arbitrarily defined as CAIX
overexpression. In addition, the cut-off values for the different
markers were: Xto 35 grey levels for HIF-1a and X10% for Ki-67.
Staining intensity was based on a scale from 0 to 3 and the
percentage of positive cells (0o1%, 1¼1–10%, 2¼10–50%,
Table 1 Correlation of clinicopathological parameters with the CAIX
expression level detected by immunohistochemistry in 555 NSCLC
patients
CAIX status
Variables Overallw Loww Highw P-value
Patient cohort 555
Mean age (years)z 63.9±9.3 64.5±8.4 65.3±5.6 0.196
Gender
a
Male 415 (75) 309 (74) 106 (26) 0.439
Female 140 (25) 111 (79) 29 (21)
Smoking history
a
Never smoked 75 (14) 54 (72) 21 (28) 0.098
Former or current smokers 480 (86) 366 (76) 114 (24)
Tumour size (cm)z 3.7±2.4 3.8±2.3 4.1±2.1 0.293
Histological cell type
a
Adenocarcinoma 281 (50) 245 ( 87) 36 (13) o0.001*
Squamous cell carcinoma 184 (33) 116 (63) 68 (37)
Large cell carcinoma 43 (8) 27 (63) 16 (37)
NOS 47 (9) 32 (68) 15 (32)
pTNM stage
a
I 278 (50) 221 (79) 57 (21) 0.676
II 103 (19) 79 (77) 24 (23)
III 151 (27) 116 (77) 35 (23)
IV 23 (4) 16 (70) 7 (30)
Histological grade
a
1 214 (38) 168 (78) 46 (22) 0.785
2 187 (34) 143 (76) 44 (24)
3 137 (25) 101 (74) 36 (26)
4 17 (3) 13 (76) 4 (24)
Neoadjuvant therapy
a 67 (12) 62 (92) 5 (8) 0.105
Abbreviations: NOS ¼ not otherwise specified; TNM ¼ tumour node metastasis.
wValues expressed as n (%) or mean±s.d.
aw
2-test. zMann–Whitney test. *P-value
significant at the 0.05 level.
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s3450%). The product of the intensity of staining and the
percentage of tumour-positive cells was then calculated to
produce an IHC score of 0 to 300, as previously described (Hassan
et al, 2008). An IHC score 440 distinguished low from high
expression of CAIX (Loncaster et al, 2001). Nuclear staining in
more than 50% of positive cells for HIF-1a and a labeling index of
Ki-67 X10% defined overexpression of both markers (Zhong et al,
1999; Woo et al, 2009). The overall score used for statistical
analysis was the mean value from three spots of the same tumour.
In parallel, whole-tissue sections from tumour blocks of a subset
of 40 cases were stained for each marker and compared with the
corresponding TMA spots using the above-mentioned scoring
criteria.
Cell culture and hypoxic exposure
The A549 lung cancer cell line (European Collection of Cell
Cultures, ECACC; passage 90, Sigma-Aldrich) was maintained in
RPMI 1640 supplemented with 10% FCS. Incubation in hypoxia at
1% O2 was carried out at 371C in 95% humidity and 5% CO2/94%
N2 in a sealed anaerobic workstation (in vivo 400; Ruskin
Technologies, Bridgend, UK).
Plasma CAIX ELISA immunoassay
Peripheral blood (5ml) was taken before surgery and kept in a
heparinised tube. Within 30min of blood collection, the samples
were centrifuged at 3000r.p.m. at 41C for 10min to separate the
plasma and blood cells. For detection of the soluble form of CAIX,
we used as an internal positive control, the culture medium of
A549 cells incubated in hypoxic conditions for 48h (Ruskin
Technologies).
ELISA commercial kits for the quantitative determination
of plasma CAIX concentrations were used according to the
manufacturer’s instructions (R&D Systems, Minneapolis, MN,
USA). Test samples (100ml) were pipetted into the wells and
incubated for 2h at room temperature on a horizontal orbital
microplate shaker (0.1200 orbit) set at 500±50r.p.m. The optical
density of each well was determined using a spectrophotometer
microplate reader (Bioelisa-iEMS Reader MF, Logiciel Ascent
Software v2.6, Labsystems, Helsinki, Finland) set to 450nm.
Results were compared with standard curves. Measurements were
done in duplicate.
Statistical methods
Analyses were performed using SPSS 16.0 statistical software (SPSS
Inc., Chicago, IL, USA). We used the w
2 and Mann–Whitney tests
to explore the association between tissue CAIX expression and the
clinicopathological variables of patients. The Mann–Whitney and
the Pearson tests were applied to assess the association between
clinicopathological variables and the CAIX plasma level. The
coefficient of correlation (r) between the expression of proteins
was calculated using the Spearman’s Rank test. The optimal
sensitivity and specificity of plasma CAIX were determined by
ROC curve analysis. In addition, the w
2 analysis was used to
determine correlations between the immunohistochemical analysis
of CAIX tissue tumour expression and the plasma CAIX ELISA
assay. The degree of agreement between data from whole-tissue
sections and the mean value of three spots was assessed using the
Cohen’s k coefficient. Survival rates were estimated using the
Kaplan–Meier method and were compared with the Log-Rank test
to determine significance. The univariate and multivariate Cox
proportional hazard models were used to determine the relative
risk. Variables that were associated with survival with a P-value
o0.20 in the univariate analysis were included in a multivariate
regression. The variables included in the model for DSS and overall
survival (OS) were pTNM stage, histological cell type and grade.
All statistical tests were two-sided, and a significant P-value was set
at the 0.05 level.
RESULTS
Immunohistochemical analysis of tissue microarrays
and correlation with the clinicopathological status
Negative or weak, intermediate, and strong CAIX membrane
staining was revealed among the different NSCLC tumours
(Figure 1A–P). In NSCLC the staining pattern for CAIX was
membranous as observed in biopsy cores of head and neck
carcinoma, used as positive control (Figure 1S–T). Tissue core
biopsies taken from normal lung tissue were negative for CAIX
expression (Figure 1Q–R).
Here, 135 of 555 (24.3%) tumours were designated as CAIX
overexpressing (Table 1). High CAIX expression was significantly
associated with histological subtypes (Po0.001). Sixty-eight
(37%) of 184 squamous cell carcinomas and 16 (37%) of 43 large
cell carcinomas overexpressed CAIX, whereas 36 (13%) of 281
adenocarcinomas overexpressed CAIX (Po0.001). No significant
correlation was found between the CAIX status and the other
clinicopathological variables (Table 1).
As for CAIX expression, the same immmunostaining intensity
pattern was observed for HIF-1a and Ki-67 expression, which
showed a nuclear staining (Supplementary Figure S1), where 133
of 555 (24%) tumours showed high HIF-1a immunoreactivity
(Supplementary Table S1). HIF-1a-positive staining was associated
Table 2 Correlation of clinicopathological parameters with the CAIX
plasma level detected by ELISA in 209 NSCLC patients
Variables Overallw
Mean CAIX level
(pgml
–1) P-value
Patient cohort 209
Mean age (years)
a 64±9.18 0.172
Genderz
Male 143 (68) 45.73 0.290
Female 66 (32) 43.15
Smoking statusz
Never smoked 21 (10) 32.37 0.330
Former or current smokers 188 (90) 46.34
Tumour size (cm)
a 4.0±2.4 0.042*
Histological cell typez
Adenocarcinoma 109 (52) 43.63 0.280
Squamous cell carcinoma 60 (29) 51.11
Large cell carcinoma 13 (6) 39.76
NOS 27 (13) 37.41
pTNM stagez
I 102 (49) 42.25 0.448
II 40 (19) 53.21
III 52 (25) 43.14
IV 15 (7) 57.19
Histological gradez
1 77 (37) 50.87 0.420
2 65 (31) 41.21
3 48 (22) 36.85
4 19 (9) 31.32
Neoadjuvant therapyz 23 (11) 40.04 0.124
Abbreviations: NOS ¼ not otherwise specified; TNM ¼ tumour node metastasis.
wValues expressed as n (%) or mean±s.d.
aPearson test. zMann–Whitney test.
*P-value significant at the 0.05 level.
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swith the histological cell type, being mainly expressed in non-
adenocarcinoma subtypes (Po0.001) and in poorly differentiated
tumours (P¼0.0001) (Supplementary Table S1).
CAIX, HIF-1a, and Ki-67 expression levels observed in the TMA
spots faithfully reflected the staining intensity of these proteins in
whole-tissue sections from corresponding tumour blocks in a
subset of 40 tumours (k¼0.89; data not shown).
Association of CAIX tumour expression with hypoxia and
proliferation
To assess the interrelationship between CAIX expression and
hypoxia or proliferation, the CAIX expression level was compared
with that of the HIF-1a and Ki-67 index, respectively, by using
the Spearman’s Rank test (Supplementary Figure S2). High CAIX
expression partially correlated with high HIF-1a expression
(r¼0.099, P¼0.023). In exchange, a w
2-test revealed significant
association between these categorical variables (P¼0.036). There
was a strong positive correlation between the CAIX expression and
the Ki-67 index (r¼0.211, Po0.001).
Plasma level of CAIX in patients with NSCLC
In patients with NSCLC, the mean value of CAIX in plasma
was 45.40 pg/ml (range: 0–372.89 pgml
 1) and was significantly
higher than in healthy individuals (mean¼2.48 pgml
 1, range:
0–16.65 pgml
 1)( Po0.001) (Figure 2A).
The subtended area of the ROC curve shows a synthetic index
of the overall capacity of the test in differentiating between
healthy individuals and NSCLC patients (Figure 2B). The area
under the ROC curve was 0.93 (CI¼0.906–0.953, Po0.001).
Using the results of the ROC curve, an analysis was made on the
test performance with respect to the different threshold values,
which showed that for a threshold equal to 11pgml
–1, plasma;
ADC
SCC
LCC
×100 ×400
SC
Ctl
Normal lung tissue Normal lung tissue HNSCC HNSCC
Figure 1 CAIX expression detected by immunohistochemistry in tissue microarray cores. Staining levels for CAIX in NSCLC histological subtypes: low
(A, E, I, M), intermediate (B, F, J, N) and strong (C, G, K, O). CAIX membrane staining in adenocarcinoma (ADC) (A–D), squamous cell carcinoma
(SCC) (E–H), large cell carcinoma (LCC) (I–L), and sarcomatoid carcinoma (SC) (M–P). Normal bronchial epithelium (Q) and alveolar tissue (R) are
devoid of staining. Strong membrane staining in head and neck squamous cell carcinoma (HNSCC) cores used as positive control of CAIX immunostaining
(S–T). Panels D, H, L, P and T are higher magnifications showing details of cells within the corresponding tumour shown on panels C, G, K, O, and S,
respectively.
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(Supplementary Table S2). Based at this cutoff we obtained a
positive predictive value of 98% and a negative predictive value
of 62%.
The mean value of CAIX in plasma obtained from NSCLC
tumours inferior to 1cm (n¼29) was 28.22pgml
–1and remained
significantly higher when compared with the mean value of CAIX
in plasma obtained from the control group (2.48pgml
–1, n¼58,
P¼0.004) (Figure 2C).
The CAIX plasma level was significantly correlated to tumour
size (P¼0.042) (Table 2). No significant association with age,
gender, smoking status, histological subtypes, or histological grade
of the tumours was noted (Table 2).
Association of the CAIX concentration in plasma with
hypoxia and proliferation
The CAIX plasma level was compared with HIF-1a expression and
the Ki-67 tumour tissues index using the Spearman’s Rank test.
There was no significant correlation of the CAIX plasma level with
these molecules (HIF-1a; r¼0.04; P¼0.90; and Ki-67; r¼ 0.02;
P¼0.82, respectively; data not shown).
Relationship between CAIX tumour expression and
outcome of patients with NSCLC
The status of CAIX as determined by immunohistochemistry on
TMA was evaluated by Kaplan–Meier analysis for association with
OS and DSS. We found that CAIX overexpression was significantly
associated with shorter OS when compared with low CAIX
expression levels (median survival time; 42 vs 55 months)
(P¼0.05) (Figure 3A). The univariate analysis revealed that CAIX
overexpression was significantly associated with worse DSS
(median survival time; 44 vs 61 months; P¼0.002) (Figure 3B).
In addition, the OS of stage IþII tumours was significantly shorter
among patients overexpressing CAIX (median survival time; 44 vs
59 months) (P¼0.034). However, no significant difference was
noted in later stage IIIþIV tumours (median survival time; 32 vs
37 months) (P¼0.56). The DSS of stage IþII tumours was
significantly shorter for those overexpressing CAIX (median
survival time; 48 vs 75 months) (P¼0.001). However, no
significant differences were noted in later stage IIIþIV tumours
(median survival time; 36 vs 37 months) (P¼0.290). Sub-
sequently, a multivariate survival analysis using the Cox’s
proportional hazard model was performed to examine the
importance of CAIX expression in patient outcome when other
prognostic factors were included (Table 3). CAIX overexpression
(RR¼0.503, CI¼0.323–0.782, P¼0.002), the disease stage
(RR¼0.388, CI¼0.268–0.562, P¼0.001) and the histological
grade (RR¼0.611, CI¼0.409–0.914, P¼0.016) were significantly
independent prognostic factors of DSS. CAIX overexpression
showed a trend as an independent prognostic factor of OS
(RR¼0.700, CI¼0.471–1.041, P¼0.068).
With regard to the correlation between CAIX and HIF-1a
tissue expression, the Kaplan–Meier analysis showed a trend
towards worse OS and DSS for patients with both high HIF-1a
and CAIX expression (P¼0.087 and P¼0.07, respectively)
(Supplementary Figure S3A, B). In addition, when HIF-1a
overexpression was evaluated by univariate analysis for a relation-
ship to outcome according to different histological subtypes,
there was a trend towards worse DSS in squamous cell carci-
nomas (median survival time; 52 vs 62 months) (P¼0.07).
In contrast, HIF-1a overexpression was not significantly asso-
ciated with survival of NSCLC patients according to the
Kaplan–Meier method or by multivariate Cox analysis (P¼0.51;
P¼0.57, respectively) (Supplementary Figure S4, Supplementary
Table S3).
The CAIX level in plasma as a biomarker of poor
prognosis in patients with NSCLC
Using an empirical thresholding method, we determined a
threshold of 100pgml
–1 (490%) plasma CAIX, as an ideal cut
off for stratification of patient survival. The mean plasma CAIX
level 4100pgml
–1 was considered as a high level of CAIX,
whereas that of p100pgml
–1was considered as a low CAIX level.
A high plasma CAIX level significantly correlated with decreased
OS (Po0.001) (Figure 3C) and DSS (Po0.001) (Figure 3D). The OS
of early-stage IþII tumours was significantly shorter among those
with a high CAIX plasma level (P¼0.003), but there was no
significant difference in later stage IIIþIV tumours (P¼0.51).
In addition, the DSS of early-stage IþII tumours was signi-
ficantly shorter among those with a high level of CAIX in the
plasma (Po0.001) when compared with later stage IIIþIV
tumours in which high CAIX was no longer associated with
survival (P¼0.23).
Multivariate analyses correlating histological subtypes, disease
stage, histological grade, and a high CAIX plasma level, showed
that a high CAIX plasma level was an independent prognostic
factor for OS (RR¼0.296, CI¼0.119–0.736, P¼0.009) and DSS
(RR¼0.102, CI¼0.032–0.330, Po0.001) (Table 3).
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Figure 2 Quantitative evaluation of the plasma CAIX level by ELISA in
patients with NSCLC and in healthy controls. (A) Box plots showing
median (central dots), 25–75% quartile ranges (boxes), and minimum/
maximum levels (whiskers) of plasma CAIX levels in healthy individuals
(n¼58) vs patients with NSCLC (n¼209). (B) ROC curve analysis of
CAIX as a plasma marker for NSCLC. X axis, 1-specificity; y axis, sensitivity.
(C) Plasma concentration of CAIX according to tumour size in NSCLC and
in healthy individuals. NS; non significant.
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in plasma
A w
2-test was used to compare CAIX immunostaining expression
in tumour samples with the CAIX values in plasma from
125 patients for whom we have performed in parallel both
measurements. We found no significant association (P¼0.919)
(Supplementary Table S4). Here, 90 of 125 (72%) patients had
low CAIX tumour expression, but it is noteworthy that they
still showed a high level of CAIX in their plasma (Supplementary
Table S4). Among these patients, 28 of 90 (31%) had lymph node
(pN1/pN2) or secondary metastatic sites (pM1).
DISCUSSION
Hypoxia is involved in biological processes promoting tumour
progression and stabilises HIF-1a, thereby controlling expression
of around a hundred genes involved in tumour metabolism,
pH regulation, angiogenesis, migration, and invasion, including
the membrane-associated CAIX protein (Semenza, 2003). CAIX
was proposed as a surrogate marker of hypoxia and is strongly
dependent on HIF-1 activation for expression (Beasley et al, 2001).
We showed that 135 of 555 (24.3%) NSCLC tumours overexpress
CAIX. In a previous series concerning 134 lung adenocarcinomas,
CAIX was overexpressed in 24.6% of cases (Kon-no et al, 2006).
In this work, there was a significantly higher expression of CAIX
in the non-adenocarcinoma histological subtypes (Po0.001), as
described (Kim et al, 2005). This is probably because of the fact
that SCC and LCC are frequently accompanied by necrosis and
CAIX is expressed predominantly around necrotic regions. This
peri-necrotic expression reflects the association of tissue tumour
CAIX with hypoxia (Kim et al, 2004). In our study, this was
supported by the positive correlation between immunostaining
for CAIX and HIF-1a expression in tumour tissue (P¼0.036).
P = 0.05
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Figure 3 Kaplan–Meier curves of overall survival (top panels A and C), and disease-specific survival (bottom panels B and D) duration stratified
according to the tissue CAIX expression detected by immunohistochemistry (left panels A and B) and the plasma CAIX levels as determined by ELISA
(right panels C and D). The cut-off value for the CAIX immunostaining score was arbitrarily defined as superior or equal to 45 grey levels. The cut-off point
for the CAIX plasma levels was empirically defined as superior or equal to 100pgml
–1. The curves are labelled with the corresponding scores.
Table 3 Multivariate Cox regression analysis of tumour tissue and plasma CAIX levels expression for OS and DSS in patients with NSCLC
Overall survival Disease-specific survival
Variables
a RR (95% CI) P-value RR (95% CI) P-value
Histologic cell type 0.612 0.363–1.032 0.065 0.619 0.328–1.171 0.140
pTNM stage 0.424 0.314–0.572 0.001* 0.388 0.268–0.562 0.001*
Histologic grade 0.663 0.479–0.919 0.014* 0.611 0.409–0.914 0.016*
High CAIX tissue expression 0.700 0.471–1.041 0.068 0.503 0.323–0.782 0.002*
Histologic cell type 0.391 0.114–1.345 0.136 0.497 0.105–2.364 0.380
pTNM stage 0.509 0.229–1.130 0.097 0.480 0.166–1.389 0.176
Histologic grade 0.538 0.202–1.435 0.215 0.254 0.074–0.871 0.029*
High plasma CAIX 0.296 0.119–0.736 0.009* 0.102 0.032–0.330 o0.001*
Abbreviations: CI ¼ confidence interval; TNM ¼ tumour node metastasis.
aCoding of variables: Histological cell type was coded as 1 (ADC) and 2 (non-ADC). pTNM stage
was coded 1 (stages I+II) and 2 (stages III+IV). Histological grade was coded 1 (grades 1 and 2) and 2 (grades 3 and 4). *P-value significant at the 0.05 level.
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sThere was no association of the CAIX level in tumour tissues with
smoking status. The occurrence of mild hypoxic condition in
smokers cannot be excluded and this could be the explanation of a
mechanism of adaptation, and therefore no increase in CAIX
expression, because of a reduced O2 supply.
The interest into CAIX expression as a prognostic factor is
currently expanding and targeted therapies directed specifically to
CAIX are being developed (Supuran, 2008). We showed that CAIX
tumour tissue expression is an independent prognostic factor for
DSS in patients with NSCLC. High CAIX expression in tissues is a
poor prognostic factor especially in early-stage IþII NSCLC for
OS (P¼0.034), and DSS (P¼0.001). This is in agreement with its
role in early tumourigenesis (Liao & Stanbridge, 2000). These
findings are consistent with previous reports on the prognostic
value of CAIX for early I/II stage resected NSCLC, in which the
percentage of CAIX-positive cells was significantly associated with
decreased OS (Kim et al, 2004). Kim et al (2005), reported that
only a percentage of CAIX-positive cells, and not the intensity of
staining, correlated with post-operative recurrence and DSS in 74
patients with early-stage NSCLC. In addition, when the perinuclear
pattern of expression was considered, Swinson et al (2003) showed
that CAIX was an independent prognostic factor for poor OS
in 175 patients with NSCLC. In the same study, cytoplasmic
CAIX and stromal expression were not associated with outcome,
and there was only a trend towards poor prognosis for high
membranous levels of CAIX in patients (Swinson et al, 2003). High
expression of the full-length (FL) CAIX isoform was related to
reduced survival of patients (Simi et al, 2006). Besides the expected
FL mRNA, a CAIX alternative splicing isoform was detected in
normal and in cancer cells, independently of the levels of hypoxia
(Barathova et al, 2008). This alternative splicing (AS) generates a
transcript lacking exons 8–9 and encodes a truncated CAIX
protein lacking the transmembrane region, the intracellular tail
and the C-terminal part of the catalytic domain. The expression of
AS CAIX mRNA was not related to survival (Malentacchi et al,
2009). Overall, the antigen expression is not so homogenous and
membranous CAIX expression seems to be detected more often
than cytoplasmic or perinuclear CAIX expression in NSCLC.
Moreover, various commercial antibodies could be the link to
heteregenous patterns of CAIX expression and therefore with a
great variability in terms of outcome. Although there is a general
agreement that detection of CAIX by IHC could predict poor
prognosis in patients with NSCLC, most studies were limited in
size and had low statistical power. The differences between our
study and similar previously reported IHC studies are the large
number of cases and the use of a high throughput TMA analysis
with automatic quantification of signals to evaluate CAIX
expression in NSCLC. We strongly believe that in a large number
of NSCLC cases we were able to prove that the detection of the
membranous CAIX expression on TMA can be used as a poor
prognostic factor in NSCLC.
In this work, HIF-1a positive immunolabelling significantly
correlated to the histological subtype (Po0.001), being mostly
expressed in SCC, as already reported (Swinson et al, 2004). It was
also related to poorly differentiated tumours (P¼0.0001), as
already shown in different types of tumours (Couvelard et al, 2005;
Trastour et al, 2007). These findings may reflect the existence of
alternative regulatory modes of HIF-1a. HIF-1a overexpression
showed a trend toward poor survival only in SCC. However, there
was no significant relationship between HIF-1a overexpression
and survival of all NSCLC patients. Our findings are supported
by those of Lee et al (2003) who showed no association between
HIF-1a expression and overall survival in 84 NSCLC patients.
In contrast to our results, other groups reported a significant
relationship between HIF-1a expression and shorter survival
(Swinson et al, 2004; Kim et al, 2005). Swinson et al (2004)
reported that only when a high positive cutoff X60% for HIF-1a
expression was used there was a significant relationship to poor
outcome of 172 NSCLC patients. In contrast, when a cutoff X
median (5%) was used as a cutoff to define negative or positive
HIF-1a staining, it was no longer related to poor survival. Kim
et al (2005) also reported a significant association between HIF-1a
overexpression with a cutoff X51.3% and tumour progression in
a series of 74 NSCLC patients. Taken together, HIF-1a expression
was reported to be associated with poor outcome of NSCLC
patients in series that used high cut-off values and also showed a
strong relationship to SCC (Swinson et al, 2004). These results are
supported by other studies that showed a significant association
between high HIF-1a expression and shorter survival in SCC of
the head and neck (Schrijvers et al, 2008). However, these results
are in disagreement with those of Volm & Koomagi (2000) who
showed that NSCLC patients with HIF-1a-positive carcinomas
had significantly longer median survival times than patients
with HIF-1a-negative carcinomas. There may be methodological
and biological explanations for some discrepancies in the results
observed in this study. One of the issues resides in the very short
half-life of HIF-1a (o10min), whereas the half-life of CAIX is
more than 24h (Rafajova et al, 2004). The second limitation
resides in the sensitivity of antibodies used for immunohisto-
chemistry. Anti-HIF-1a antibodies have always been problematic,
whereas the immunogenicity of the CAIX antibody is excellent
with no non-specificity (Lam et al, 2005). Also, the variability in
the results may be due to the cut-off point used to define cases as
overexpressing HIF1-a. In this study, we have used a 45 grey-levels
threshold for a semi-automated analysis corresponding to a cutoff
X18%. This is somewhat lower than that used in several studies
showing a strong correlation with poor outcome.
One explanation for CAIX being discriminatory as a prognostic
biomarker resides in the fact that all cells exposed to hypoxia, and
therefore to a rapid proliferation, will become hypoxic and HIF-1a
positive, but not necessarily CAIX positive. In many tissues,
HIF-1a may not be sufficient to induce CAIX and only several
oncogenic steps associated to epigenetic changes leading to
chromatin remodeling will ‘uncover’ the ca9 gene and make it
permissive and inducible by HIF-1. We hypothesize that NSCLC in
which CAIX is expressed present a more aggressive phenotype.
This hypothesis is supported by our data on healthy lung tissue
exposed to hypoxia (1% O2) for 24h. Although hypoxia-induced
HIF-1a stabilisation was detected by IHC on normal tissue, there
was no CAIX expression (Supplementary Figure S5). Instead, we
observed increased expression of BNIP3 and BNIP3L, two proteins
whose expression is enhanced by HIF-1 (Guo et al, 2001). In this
regard, further studies must be performed to check BNIP3 and
BNIP3L status in the different tumour tissues. Moreover, for
the subpopulation with high HIF-1a expression, we showed that
HIF-1a required CAIX expression to predict a trend towards poor
OS and DSS. This may suggest that expression of HIF-1a alone
may not be enough to affect the malignant potential of all NSCLC,
but rather requires the expression of HIF-1a-regulated genes.
Recent studies have shown that soluble CAIX is being shed from
the tumour cells into the culture medium and plasma or urine of
renal cancer patients (21). This corresponds to the extracellular
part of the CAIX molecule, which is composed of the proteoglycan
(PG)-like and CA domains that are cleaved off the plasma
membrane (Zavada et al, 2003). Our study reports that the plasma
CAIX level in NSCLC patients is significantly higher than in
healthy individuals (Po0.001). Nevertheless, we showed that the
plasma CAIX detected in patients with NSCLC is much lower than
CAIX concentrations described in renal cell carcinoma, because
the very high constitutive HIF-1a levels in these latter tumours and
also differences in CAIX expression depending on the cell type
(Li et al, 2008). Increased levels of plasma CAIX have been
reported only in urological cancers (Zavada et al, 2003; Li et al,
2008; Hyrsl et al, 2009). Thus, our report is the first study to show
evidence of high CAIX levels in the plasma of NSCLC patients.
Our data show that the CAIX ELISA had a very good sensitivity
Carbonic anhydrase IX in non-small cell lung cancer
MI ˙lie et al
1633
British Journal of Cancer (2010) 102(11), 1627–1635 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s(84%) and specificity (95%). Moreover, even for tumours inferior
to 1cm in size, the mean value of CAIX was significantly higher
when compared with the mean value of CAIX plasma in the control
group. It appears that there is no increase in CAIX in the plasma
of patients bearing tumours larger than 2cm when compared
with smaller tumours (o1cm). This is unlikely to be explained
by the loss of differentiation because in our study there was no
correlation with the histological grade. In the earlier stages of
tumour progression, conditions such as hypoxia or ischemia may
induce a high CAIX plasma level as an adaptation to confer a
proliferative advantage for tumour growth and spread. However,
when this malignant potential is attained in later stages of tumour
growth, continued shedding of CAIX into the plasma might no
longer be required. The difference in the CAIX plasma level may
reflect distinct molecular pathways and genetic alterations that
impact small-sized tumours, which may determine the subsequent
development and risk of progression, as already suggested for
bladder cancers (Turner et al, 2002). On the other hand, the
cumulative effects of genetic lesions involved in cancer progression
could alter the pathways of the hypoxic response and therefore
could affect the CAIX plasma level (Rak et al, 2002). This is in
agreement with the lack of correlation between the plasma CAIX
level and Ki-67 index observed in our study. Surprisingly, the
CAIX plasma level was not related to HIF-1a detection as observed
with IHC (r¼0.04, P¼0.90). Moreover, there was no correlation
with SCC or LCC subtypes as we observed in the case of
immunodetected CAIX. With regard to the relationship between
membranous CAIX and HIF-1a detection, this finding is raising a
question on whether and how HIF-1a could influence the CAIX
shedding from tumour cell surface.
Although our observations were inconsistent with the proposal
that hypoxia and HIF-1 are the sole regulators of CAIX expression
and thus shedding (Zatovicova et al, 2005), one cannot exclude
that shedding occurs at hypoxic metastatic sites. Although the
precise molecular mechanism of regulated CAIX shedding remains
to be clarified, previous studies showed that dysregulation of
HIF-1a could be caused by mutation in the von Hippel-Lindau
(VHL) tumour suppressor gene or activation of the epidermal
growth factor receptor (EGFR) (Semenza, 2003). Mutated VHL
prevents appropriate normoxic degradation of HIF-1a and, as
such, CAIX is highly expressed in mutated VHL-related tumours,
independently of the extent of tumour necrosis (Swinson et al,
2003). VHL gene mutations have been previously shown in a
proportion of cell lines derived from small-cell lung cancer,
NSCLC, carcinoids, and mesotheliomas (Sekido et al, 1994). VHL
mutations may be present in a subgroup of patients with negative
CAIX expression in tumour tissue but with a high plasma level of
CAIX. With regard to EGFR signaling, in vitro studies showed that
signaling through the EGF pathway by phosphorylation of a
cytoplasmic tyrosine residue of CAIX may either activate CAIX
or enhance its expression (Dorai et al, 2005). In addition,
phosphorylation activates phosphatidylinositol 3-kinase, resulting
in phosphorylation of Akt and cancer cell survival (Dorai et al,
2005). This suggests that EGFR activation may also increase
induction of CAIX, and therefore the shedding of the CAIX
ectodomain. Moreover, the basal level of tissue CAIX may be
sufficient for shedding and the soluble form of CAIX may finally
represent tumour progression. Our results support this hypothesis
as we showed that a high plasma CAIX level was an independent
prognostic factor significantly related to worse OS and DSS of
early-stage IþII NSCLC when compared with later stage IIIþIV
NSCLC.
When the correlation between CAIX expression levels as
determined by ELISA and immunohistochemistry was assessed,
we did not find any relationship. This indicates that the two
methods are not directly interchangeable and that their value for
clinical purposes may be different. Overall, when we take into
account the intratumoural heterogeneity and the different
controversial results regarding the value of tissue tumour CAIX
expression as a prognostic factor, we postulate that the detection of
the soluble form of CAIX in plasma patients can be a more reliable
prognostic factor of worse OS and DSS in patients with early-stage
NSCLC.
This study shows that CAIX tumour tissue expression as
detected by immunohistochemistry on TMA, can serve as an
important predictor for survival in patients with NSCLC. More-
over, we showed that the plasma CAIX level is an independent
prognostic factor in early-stage NSCLC. Our results support the
high specificity and the potentiality of plasma CAIX as a helpful
clinical biomarker for detection of NSCLC at an early stage.
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